Skip to main content

Advertisement

Table 6 Simulated % ACPR28 with 90% confidence intervals for single dose combinations of artefenomel and PQP in non-vomiting African children ≤ 5 years old

From: A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria

PQP adult-equivalent dose, mg   Artefenomel adult-equivalent dose, mg
  0 200 400 800 1200 1600
0 NR (–) 22 (14–32) 39 (29–49) 70 (59–79) 86 (78–92) 94 (88–97)
320 27 (18–37) 35 (28–44) 52 (45–59) 79 (73–84) 91 (86–94) 96 (93–98)
640 40 (29–52) 48 (39–58) 64 (58–70) 85 (81–88) 94 (91–96) 97 (95–99)
960 51 (38–64) 59 (48–69) 72 (65–78) 89 (85–92) 95 (93–97) 98 (97–99)
1440 64 (49–76) 70 (59–80) 80 (73–86) 92 (89–95) 97 (95–98) 99 (98–99)
2000 74 (59–85) 79 (67–88) 86 (80–91) 95 (93–97) 98 (97–99) 99 (98–100)
2800 83 (70–91) 86 (76–93) 91 (85–95) 97 (95–98) 99 (98–100) > 99 (99–100)
3600 88 (78–95) 91 (83–96) 94 (90–97) 98 (96–99) 99 (99–100) > 99 (99–100)
  1. For the stimulations, the identified age effect on artefenomel PK was not included; it was assumed, therefore, that exposures in the youngest patients were similar to those in the older age groups. NR not reported
  2. Predicted ACPR28 > 95%; outcome predicted with a lower bound > 95%